ACM
MYGN icon

Aster Capital Management’s Myriad Genetics MYGN Stock Holding History

Aster Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,611
Closed -$38.7K – 1390
2025
Q1 		$38.7K Buy
3,611
+3,287
+1,015% +$39.5K 0.01% 871
2024
Q4 		$4.44K Sell
324
-20,134
-98% -$372K ﹤0.01% 873
2024
Q3 		$560K Buy
+20,458
New +$554K 0.12% 190

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Aster Capital Management's MYGN Position: Q2 2025 in Review

Aster Capital Management sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 3,611 shares — an estimated $38.7K sold.

Aster Capital Management first reported a position in MYGN in Q3 2024 and held it in 3 quarters. The position peaked at $560K in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • Aster Capital Management reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • Aster Capital Management sold 3,611 Myriad Genetics shares in Q2 2025, an estimated $38.7K.
  • Aster Capital Management first reported a position in Myriad Genetics in Q3 2024 and held it in 3 quarters.
  • Aster Capital Management's Myriad Genetics position peaked at $560K in Q3 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Aster Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.